Unsaturated Aliphatic Compound Patents (Class 514/744)
  • Publication number: 20150018429
    Abstract: This invention relates to azeotrope-like compositions, methods and systems having utility in numerous applications, and in particular, uses for azeotrope-like compositions comprising effective amounts of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: and another material selected from the group consisting of water, fluoroketones, alcohols, hydrochlorofluoroolefins, and combinations of two or more thereof. These compositions may be used in a wide variety of applications such as, blowing agents, refrigerants, heating agents, power cycle agents, cleaning agents, aerosol propellants, sterilization agents, lubricants, flavor and fragrance extractants, flammability reducing agents, and flame suppression agents.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Ryan Hulse, Rajiv Ratna Singh, Martin R. Paonessa, Martin Cheney, Hang T. Pham, Mary Bogdan, Cliff Gittere
  • Publication number: 20140037743
    Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.
    Type: Application
    Filed: October 11, 2013
    Publication date: February 6, 2014
    Applicant: DelivRx, Inc.
    Inventor: Daniel R. DeBrouse
  • Publication number: 20130287830
    Abstract: Vehicles for delivery and release of pesticide compositions are provided. In one aspect, the delivery vehicle is a capsule configured to resist release of a pesticide composition before application of the capsule at a locus where pest control is desired. The capsule is further configured to degrade following application at the locus where pest control is desired to facilitate release of the pesticide composition. In one particular but non-limiting form, the capsule includes a shell wall including a relatively high Bloom strength gelatin material and a plasticizer material, and the pesticide composition includes a fumigant such as 1,3-dichloropropene. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings.
    Type: Application
    Filed: April 25, 2013
    Publication date: October 31, 2013
    Applicant: Dow AgroSciences LLC
    Inventors: Lorenzo Aulisa, John D. Busacca, Donald E. Williams,, III, Phillip J. Howard, Ashish Batra, Sara J. Linder
  • Publication number: 20130217784
    Abstract: Disclosed are the use of fluorine substituted olefins, including tetra- and penta-fluoropropenes, in a variety of applications, including in methods of depositing catalyst on a solid support, methods of sterilizing articles, cleaning methods and compositions, methods of applying medicaments, fire extinguishing/suppression compositions and methods, flavor formulations, fragrance formulations and inflating agents.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 22, 2013
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventor: HONEYWELL INTERNATIONAL INC.
  • Publication number: 20130203844
    Abstract: The invention relates to the use of a composition comprising at least one volatile molecule specific to the estrus of cows in order to improve the reproductive function of a bull. In particular, the composition according to the invention makes it possible to act on the libido of the bull, but also on the production of semen by the bull. Preferably, the composition used comprises at least one molecule from among coumarin, squalene, 6-amino undecane, 2-butanone, 9-octadecenoic acid and 1,2-dichloroethylene.
    Type: Application
    Filed: March 28, 2011
    Publication date: August 8, 2013
    Inventors: Patricia Meillour, Chrystelle Le Danvic, Patrice Humblot, Philippe Chemineau, Christine Briant, Olivier Gerard
  • Publication number: 20130109570
    Abstract: Fumigant compositions including hexafluoropropene or 1,1,3,3,3-pentafluoropropene, and methods of preparing such compositions, are provided herein. The fumigant compositions may be suitable for use as soil fumigant compositions and structural fumigant compositions against a variety of undesirable species such as weeds, nematodes, pathogens, animals and insects. The fumigant compositions also have low toxicity and low Global Warming Potential.
    Type: Application
    Filed: October 15, 2012
    Publication date: May 2, 2013
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventor: HONEYWELL INTERNATIONAL INC.
  • Publication number: 20120213861
    Abstract: Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 23, 2012
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventors: Andrew Joseph Poss, Rajiv Ratna Singh, David Nalewajek, Cheryl Cantlon
  • Publication number: 20120004299
    Abstract: This invention relates to azeotrope-like compositions, methods and systems having utility in numerous applications, and in particular, uses for azeotrope-like compositions comprising effective amounts of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: and another material selected from the group consisting of water, fluoroketones, alcohols, hydrochlorofluoroolefins, and combinations of two or more thereof. These compositions may be used in a wide variety of applications such as, blowing agents, refrigerants, heating agents, power cycle agents, cleaning agents, aerosol propellants, sterilization agents, lubricants, flavor and fragrance extractants, flammability reducing agents, and flame suppression agents.
    Type: Application
    Filed: December 14, 2010
    Publication date: January 5, 2012
    Applicant: Honeywell International Inc.
    Inventors: Ryan Hulse, Rajiv Ratna Singh, Martin R. Paonessa, Hang T. Pham, Mary Bogdan, Cliff Gittere, Martin Cheney, Linda L. Cheney
  • Publication number: 20110245350
    Abstract: A process is disclosed for making CF3CF?CH2 or mixtures thereof with CHF?CFCHF2. The process involves contacting CCl3CF2CF3 and optionally CCl2FCF2CClF2 with H2 in the presence of a catalyst including a catalytically effective amount of palladium supported on a support of alumina, fluorided alumina and/or aluminum fluoride, to produce a product mixture including CH2?CFCF3 (and when CCl2FCF2CClF2 is present, CHF?CFCHF2); recovering CH2?CFCF3 or a mixture thereof with CHF?CFCHF2 from the product mixture; and optionally, separating at least a portion of any CHF?CFCHF2 in the product mixture from the CH2?CFCF3 in the product mixture. The mole ratio of H2 to the total of CCl3CF2CF3 and CCl2FCF2CClF2 fed to the reaction zone is between about 1:1 and about 5:1.
    Type: Application
    Filed: June 9, 2011
    Publication date: October 6, 2011
    Applicant: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: MARIO JOSEPH NAPPA, Velliyur Nott Mallikarjuna Rao, Allen Capron Sievert
  • Publication number: 20110152226
    Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.
    Type: Application
    Filed: September 15, 2010
    Publication date: June 23, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas S. Scanlan, Martin J. Kelly, Jian Qiu, Sandra Tobias, Oline K. Ronnekleiv
  • Patent number: 7695635
    Abstract: An azeotropic or azeotrope-like composition comprising a mixture of methyl iodide, 1-chloro-3,3,3,-trifluoropropene, and optionally one or more of fluorocarbons and/or hydrofluorocarbons. The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: April 13, 2010
    Assignee: Honeywell International Inc
    Inventors: Rajiv R. Singh, Hang T. Pham, Andrew J. Poss
  • Patent number: 7544306
    Abstract: Azeotropic and azeotrope-like compositions of methyl iodide and at least one fluorocarbon or hydrofluorocarbon such as 1,1,1,3,3-pentafluoropropane (HFC-245fa). The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: June 9, 2009
    Assignee: Honeywell International Inc.
    Inventors: Andrew J. Poss, Rajiv R. Singh, Hang T. Pham
  • Patent number: 7488854
    Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 10, 2009
    Assignees: The National Institute of Agrobiological Sciences, Riken
    Inventors: Shigemi Seo, Yuko Ohashi, Hideharu Seto, Shigeo Yoshida
  • Publication number: 20080287429
    Abstract: A group of pharmaceutical substances induce elevation of endogenous bile salts and acids via different mechanisms. The elevated circulating bile salts exert a beneficial effect in atherosclerosis by acting both as atherolytic and antiatherogenic agents. The result of the elevated circulating endogenous bile salt is the dissolution of cholesterol/lipidic aggregates of the atherosclerotic plaques.
    Type: Application
    Filed: May 15, 2008
    Publication date: November 20, 2008
    Applicant: Z & Z Medical Holdings, Inc.
    Inventors: Filiberto P. Zadini, Giorgio C. Zadini
  • Patent number: 7037511
    Abstract: Cosmetic or dermatological stick preparations, which are finely disperse systems of the water-in-oil type, comprising a) an oil phase which ?comprises from 10 to 70% by weight, based on the weight of the fatty phase, of fatty and/or wax components which melt above a temperature of 40° C., b) a water phase, c) at least one modified phyllosilicate which exhibits both hydrophilic and also lipophilic properties, which thus has amphiphilic character and positions itself at the water/oil interface, and d) at most 0.5% by weight of one or more emulsifiers and method for their preparation.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: May 2, 2006
    Assignee: Beiersdorf AG
    Inventors: Heinrich Gers-Barlag, Anja Müller, Xenia Petsitis, Ghita Lanzendörfer, Melanie Kovacevic
  • Patent number: 6861451
    Abstract: Carboxylic acid fluorides having a boiling point of preferably less than 100° C. are suitable for use as pesticides. Acetyl fluoride is highly suitable, and Chlorodifluoroacetyl fluoride and trifluoroacetyl fluoride are also very useful. Mixtures of carboxylic acid fluoride pesticides and other pesticides are also disclosed.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: March 1, 2005
    Assignee: Solvay Fluor und Derivate GmbH
    Inventors: Max Braun, Francine Janssens, Reiner Fischer
  • Publication number: 20040147617
    Abstract: Propargyl bromide is effectively stabilized against shock or thermal decomposition by use therewith of an environmentally acceptable inert liquid solvent that forms an azeotrope with propargyl bromide.
    Type: Application
    Filed: January 12, 2004
    Publication date: July 29, 2004
    Inventors: Robert C. Herndon, Robert H. Allen, Noel H. Brantley, Hassan Y. Elnagar, Ronny W. Lin, Ralph W. Magin, Mahmood Sabahi
  • Patent number: 6514963
    Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: February 4, 2003
    Assignee: The Regents of the University of California
    Inventors: Mark Walter, Armand Kuris
  • Patent number: 6506800
    Abstract: Pesticidal 1,4-diaryl-2,3-difluoro-2-butene compounds of formula I wherein Ar is phenyl, 1- or 2-naphthyl or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted; R is C2-C6-alkenyl, C4-C6-cycloalkenyl or C1-C2-alkoxy-C2-C6-alkyl; and Ar1 is phenoxyphenyl, phenyl, biphenyl, phenoxypyridyl, benzylpyridyl, benzylphenyl, benzoylphenyl, 1- or 2-naphthyl, or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted, intermediates and methods for the preparation of compounds of formula I and compositions and methods comprising the compounds and compositions for the control of insect and acarid pests.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: January 14, 2003
    Assignee: BASF Aktiengesellschaft
    Inventor: Terence James Bentley
  • Patent number: 6492399
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine, (4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(5-hydroxypyridin)yl)-4-penten-2-amine.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: December 10, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Srishailkumar Basawannappa Hadimani
  • Patent number: 6254876
    Abstract: A composition suitable for topical application, comprising a liquid fatty phase, at least one dye, and at least 2% by weight, relative to the total weight of the composition, of polymer particles which are dispersed and stabilized at the surface by at least one stabilizer in the liquid fatty phase. The present invention also provides a composition suitable for topical application, comprising a cosmetic, dermatological, hygiene or pharmaceutical liquid fatty phase, at least one active agent selected from the group consisting of cosmetic, dermatological, hygiene and pharmaceutical active agents, and at least 2% by weight, relative to the total weight of the composition, of polymer particles which are dispersed and stabilized at the surface by at least one stabilizer in the liquid fatty phase.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: July 3, 2001
    Assignee: L'Oreal
    Inventors: Valérie de la Poterie, Nathalie Mougin
  • Publication number: 20010001657
    Abstract: One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.
    Type: Application
    Filed: April 4, 1997
    Publication date: May 24, 2001
    Inventors: MICHEL SCHNEIDER, FENG YAN, PASCAL GRENIER, NADINE GARCEL, JEROME PUGINIER, MARIE-BERNADETTE BARRAU
  • Patent number: 6083498
    Abstract: Compositions and lures are described which provide vapor blends of acetic acid and one or more compounds selected from the group consisting of isobutanol, racemic 2-methyl-1-butanol, S-(-)-2-methyl-1-butanol, 2-methyl-2-propanol, heptyl butyrate, and butyl butyrate which function as highly effective attractants for yellowjacket wasps and paper wasps. By attracting wasps to traps or baits, the chemical attractants provide a means for detecting, surveying, monitoring, and controlling the wasps.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: July 4, 2000
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventor: Peter J. Landolt
  • Patent number: 6008209
    Abstract: This invention provides a method of treating or preventing neoplastic diseases. The method comprises adminstering to a host in need of such treatment or prevention an effective amount of a Vitamin D.sub.3 analog of the Formula I wherein:X is H.sub.2 or CH.sub.2 ;Y is hydrogen, hydroxy or fluorine;Z is hydroxy;R.sub.1 and R.sub.2 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.1 and R.sub.2 together with C.sub.25 form a (C.sub.3 -C.sub.6) cycloalkyl or cyclofluoroalkyl;R.sub.3 and R.sub.4 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.3 and R.sub.4 together with C.sub.25' form a (C.sub.3 -C.sub.6)cycloalkyl or cyclofluoroalkyl;A is a single bond or a double bond;B.sub.1 is a single bond, an E-double bond, a Z-double bond or a triple bond; andB.sub.2 is a single bond, an E-double bond, a Z-double bond or a triple bond; or a prodrug thereof.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: December 28, 1999
    Assignees: Hoffmann-La Roche Inc., Syntex (U.S.A.)
    Inventors: Percy Sarwood Manchand, Milan Radoje Uskokovic
  • Patent number: 5989918
    Abstract: A method for analyzing the ADME/PK properties of a mixture of compounds is (1) perfusing an animal or organ with a perfluorocarbon emulsion blood substitute, (2) administering the mixture of test compounds, (3) withdrawing an aliquot of the perfusate, (4) disrupting the emulsion, and (5) analyzing the aqueous phase of the perfusate for the concentration of test compounds.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: November 23, 1999
    Assignee: Chiron Corporation
    Inventors: Corine M. Dietz, Jacqueline A. Gibbons, Eric W. Taylor
  • Patent number: 5858389
    Abstract: A method and composition for treatment of hepatitis C virus (HCV), administered as two component treatment, involving 1) an orally administered squalene in combination with 2) the inhalation of squalene medication. Each medication component must be administered concurrently.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: January 12, 1999
    Assignee: Shaker H. Elsherbini
    Inventor: Shaker Hamed Elsherbini
  • Patent number: 5859068
    Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: January 12, 1999
    Assignee: Children's Medical Center Corporation
    Inventor: Jay M. Wilson
  • Patent number: 5851510
    Abstract: A heat and shelf-stable oil-in-water emulsion useful as a tissue or cell-selective delivery vehicle. Radioactive or stable, synthetic or semi-synthetic polyhalogenated triglycerides, such as 2-oleoylglycerol-1,3-bis?7-(3-amino-2,4,6-triiodophenyl)heptanoate! or 2-oleoylglycerol-1,3-bis?.omega.-(3,5-bis-trifluoromethyl)heptanoate! or phenyl acetate, can be incorporated into the lipophilic core of a lipoprotein-like emulsion particle. The lipophilic core is surrounded by a phospholipid membrane comprising cholesterol and apolipoproteins. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm as measured by number weighting analysis with a narrow size distribution (<2% greater than 300 nm) and having a composition simulating naturally-occurring chylomicron remnants. Use of cholesterol in the emulsion formula facilitates association of apolipoproteins, especially Apo E which are recognized by liver cells and necessary for binding and uptake.
    Type: Grant
    Filed: May 16, 1994
    Date of Patent: December 22, 1998
    Assignee: The Board of Regents of The University of Michigan
    Inventors: Raymond E. Counsell, Marc A. Longino, Jamey P. Weichert, Douglas A. Bakan
  • Patent number: 5849317
    Abstract: Disclosed are methods and compositions for retarding the movement of ants, wasps, and/or termites to a specific locus by use of farnesol or a farnesol related compound.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: December 15, 1998
    Assignee: Regents of the University of California
    Inventors: Harry H. Shorey, Lyle K. Gaston
  • Patent number: 5684050
    Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: November 4, 1997
    Assignee: HemaGen/PFC
    Inventors: Leland C. Clark, Jr., Robert Francis Shaw
  • Patent number: 5662914
    Abstract: Disclosed are methods and compositions for retarding the movement of ants, wasps, and/or termites to a specific locus by use of farnesol or a farnesol related compound.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: September 2, 1997
    Assignee: The Regents of the University of California
    Inventors: Harry H. Shorey, Lyle K. Gaston
  • Patent number: 5614562
    Abstract: Organoselenones of the formulaR.sub.1 --Se(O.sub.2)--(CH.sub.2).sub.n --Xwherein R.sub.1 is selected from the group consisting of aryl, vinyl, acetylenyl, and aralkyl, n is an integer equal to 2 to 6 and X is a leaving group selected from the group consisting of halides, sulfonates and selenones; were surprisingly found to be useful as alkylating agents which possessed a high degree of selectivity for nitrogen nucleophiles without the usual increased preference for sulfur nucleophiles. This property allows the effective use of these compounds as anti-cancer alkylating agents suitable for use in drug-resistant cell lines which display either thiol mediated drug resistance or MER(+)-mediated drug resistance. Two methods of synthesizing these compounds are also provided.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: March 25, 1997
    Assignee: The University of Sourthern California
    Inventors: Colin P. Spears, Sang-Ihn Kang
  • Patent number: 5582813
    Abstract: The present invention relates to nonterminally iodinated fluorinated compositions. The compositions, including, dispersions, emulsions, microemulsions, and gels are useful for biomedical applications, particularly radiography and scintigraphy. The compounds used in the invention preferably have the following general formula:R.sub.F CH.dbd.CIR.sup.1wherein,R.sub.F is a linear, branched, or cyclic first fluorocarbon radical, having 2 to 12 carbon atoms in which 50 to 100% of the hydrogen atoms have been replaced by fluorine atoms; andR.sup.1 is selected from the group consisting of a second fluorocarbon radical and a hydrocarbon radical, wherein,the second fluorocarbon radical is linear, branched, or cyclic, having 2 to 12 carbon atoms in which 50 to 100% of the hydrogen atoms have been replaced by fluorine atoms; andthe hydrocarbon radical is linear, branched, or cyclic, having 2 to 14 carbon atoms.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: December 10, 1996
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jean G. Riess, Leila Zarif, Veronique Sanches, Jacques Greiner
  • Patent number: 5578292
    Abstract: One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: November 26, 1996
    Assignee: Bracco International B.V.
    Inventors: Michel Schneider, Feng Yan, Pascal Grenier, deceased, Jerome Puginier, Marie-Bernadette Barrau
  • Patent number: 5573751
    Abstract: Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or "microbubbles," comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of a microbubble comprised of the gas.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: November 12, 1996
    Assignee: Sonus Pharmaceuticals, Inc.
    Inventor: Steven C. Quay
  • Patent number: 5558854
    Abstract: Ultrasound contrast media comprising gaseous perfluoropentane and gaseous perfluorohexane are disclosed.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: September 24, 1996
    Assignee: Sonus Pharmaceuticals
    Inventor: Steven C. Quay
  • Patent number: 5480914
    Abstract: Nonaqueous thixotropic drug delivery vehicles for use in aqueous physiological systems are disclosed comprising a substantially homogeneous dispersion of at least one suspending aid in a nonaqueous perfluorocarbon or fluorinated silicone liquid carrier. Pharmaceutical compounds may be incorporated to provide thixotropic pharmaceutical compositions having improved delivery profiles and high drug localization. The thixotropic compositions act as free-flowing, drop-instillable liquids upon the application of stress yet behave as a visco-elastic material when at rest. Due to these thixotropic properties the pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not degrade the incorporated therapeutic or diagnostic compounds making them well suited for multidose packaging and administration.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: January 2, 1996
    Assignee: Allergan, Inc.
    Inventor: David L. Meadows
  • Patent number: 5439944
    Abstract: Oil and water emulsions containing alkylphosphoryl choline or alkylglycerophosphoryl choline surfactants are disclosed. The surfactants have the following general structures: ##STR1## In the above general structures, R.sub.1, R.sub.2 or R.sub.3 is alkyl, alkenyl, fluoroalkyl and alkenyl; and PC is the phosphoryl choline. The emulsions are useful as oxygen transport agents, artificial bloods or red blood cell substitutes.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: August 8, 1995
    Assignee: HemaGen/PFC
    Inventors: Robert J. Kaufman, Thomas J. Richard
  • Patent number: 5409688
    Abstract: Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or "microbubbles," comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.
    Type: Grant
    Filed: June 5, 1992
    Date of Patent: April 25, 1995
    Assignee: Sonus Pharmaceuticals, Inc.
    Inventor: Steven C. Quay
  • Patent number: 5407962
    Abstract: Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic compound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: April 18, 1995
    Assignee: HemaGen/PFC
    Inventors: Robert J. Kaufman, Thomas J. Richard
  • Patent number: 5393513
    Abstract: A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: February 28, 1995
    Assignee: Alliance Pharmaceutical Corp.
    Inventor: David M. Long, Jr.
  • Patent number: 5393524
    Abstract: Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or "microbubbles," comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of a microbubble comprised of the gas.
    Type: Grant
    Filed: June 4, 1993
    Date of Patent: February 28, 1995
    Assignee: Sonus Pharmaceuticals Inc.
    Inventor: Steven C. Quay
  • Patent number: 5350571
    Abstract: Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic compound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: September 27, 1994
    Assignee: HemaGen/PFC
    Inventors: Robert J. Kaufman, Thomas J. Richard
  • Patent number: 5283383
    Abstract: The present invention relates to a new antitumor compound, a method for isolating same from a red alga, antitumor compositions containing same and methods of using same for treating patients with cancer. The compound of the present invention is 6(R)-bromo-3(S)-bromomethyl-7-methyl-2,3,7-trichloro-1-octene.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: February 1, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Richard W. Fuller, Kenneth M. Snader, Jon Clardy
  • Patent number: 5238930
    Abstract: Alkenoic acid compounds are described. The compounds which are dehydropeptidase inactivators contain a ##STR1## moiety which is substituted with a halomethylene or a cyano moiety as R.sub.3. The enzyme deprotonates the alpha--CH.sub.2 group and then the intermediate compound forms a covalent bond with enzymic residue in the active site, resulting in irreversible inactivation of the enzyme. The compounds are particularly inactivators of renal dipeptidases.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: August 24, 1993
    Assignee: Board of Governors of Wayne State University
    Inventor: Shahriar Mobashery
  • Patent number: 5080885
    Abstract: A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.
    Type: Grant
    Filed: August 24, 1989
    Date of Patent: January 14, 1992
    Assignee: Alliance Pharmaceutical Corp.
    Inventor: David M. Long, Jr.
  • Patent number: 5077036
    Abstract: Biocompatible fluorcarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: December 31, 1991
    Assignee: Alliance Pharmaceutical Corp.
    Inventor: David M. Long, Jr.
  • Patent number: 4876285
    Abstract: Nematodes and insects are controlled by application of vinyl fluorides of the formula ##STR1## where R is CH.sub.2 X--, CHX.sub.2 --, CX.sub.3 --, XCH.dbd.CH--, CH.sub.2 .dbd.CX-- or straight chain alkyl(C.sub.2 -C.sub.8);R.sup.1 is hydrogen, fluoro, chloro, bromo, CH.sub.2 Z--, CHZ.sub.2 -- or CZ.sub.3 --;R.sup.2, X and Z independently are hydrogen, fluoro, chloro or bromo; Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 independently are CH.sub.3 or any value of R.sup.2, X and Z; a is 0-12; n is 7-13; and n is greater than a.Particular species controlled are the root-knot, stunt, lesion, cyst and free-living nematodes, and the southern corn rootworm. The vinyl fluorides also have anthelmintic utility.
    Type: Grant
    Filed: March 2, 1987
    Date of Patent: October 24, 1989
    Assignee: FMC Corporation
    Inventor: Clinton J. Peake
  • Patent number: 4849211
    Abstract: A composition comprising squalene and saturated normal aliphatic hydrocarbons which is very effective in the treatment of acne, minor skin irritations and minor skin wounds, burns, inflammation and soreness when applied topically to the skin. Basically, the product comprises from about 5 to 40 volume percent squalene and from about 5 to 25 volume percent n-decane, n-dodecane or mixtures thereof with the balance being normal aliphatic hydrocarbons with chain lengths in the C10 to C35 range or a water-polysorbate emulsion. If desired, certain other ingredients such as zinc oxide or a filler may be added to the mixture. The product may be applied as a spray, cream or gel.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: July 18, 1989
    Inventor: Gerhard N. Schrauzer
  • Patent number: RE38459
    Abstract: An injectable physiologically acceptable aqueous phase fluorocarbon emulsion, which has substantially no free fluorocarbon, has an excellent stability is prepared by a process of the invention. Typically, more than about 99.8 wt. % of the fluorocarbon remains in the size range of about 0.2 to 0.4 microns even after being stored at room temperature for one year or more in sealed containers under a non-oxidizing atmosphere. The emulsion is useful in medical applications, for example, coronary angioplasty, cancer therapy, among others.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: March 9, 2004
    Assignee: Thomas Jefferson University
    Inventors: Stuart Raynolds, Robert H. Dettre